Most Surveyed Clinicians Will Prescribe Amgen/GlaxoSmithKline's Prolia as Either a Second- or Third-Line Therapy for Osteoporosis

Thursday, December 3, 2009 General News
Email Print This Page Comment bookmark
Font : A-A+

More Than Half of Surveyed MCOs Will Place Prolia, Pfizer's Viviant and Pfizer/Ligand Pharmaceuticals' Aprela on Tier 3 or Higher in Their Formularies, According to a New Report from Decision Resources

For more information, contact:

Decision Resources

Decision Resources, Inc.

Christopher Comfort

Elizabeth Marshall

781-296-2597

781-296-2563

[email protected]

[email protected]



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store